Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $63.0 million.

  • Foghorn Therapeutics' Shares Outstanding (Diluted Average) rose 68.12% to $63.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 68.12%. This contributed to the annual value of $54.9 million for FY2024, which is 3079.24% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Shares Outstanding (Diluted Average) is $63.0 million, which was up 68.12% from $63.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $63.0 million for Q3 2025, and its period low was $36.8 million during Q1 2021.
  • For the 5-year period, Foghorn Therapeutics' Shares Outstanding (Diluted Average) averaged around $46.4 million, with its median value being $41.8 million (2023).
  • Per our database at Business Quant, Foghorn Therapeutics' Shares Outstanding (Diluted Average) surged by 57998.69% in 2021 and then skyrocketed by 68.12% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Shares Outstanding (Diluted Average) stood at $37.2 million in 2021, then grew by 11.89% to $41.6 million in 2022, then grew by 0.92% to $42.0 million in 2023, then soared by 30.79% to $54.9 million in 2024, then increased by 14.81% to $63.0 million in 2025.
  • Its last three reported values are $63.0 million in Q3 2025, $63.0 million for Q2 2025, and $62.8 million during Q1 2025.